Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer

Lung Cancer ◽  
2010 ◽  
Vol 68 (2) ◽  
pp. 295-298 ◽  
Author(s):  
Im Il Na ◽  
Du Hwan Choe ◽  
Cheol Hyeon Kim ◽  
Jae Soo Koh ◽  
Baek-Yeol Ryoo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Age At Diagnosis ◽  
Small Cell Lung ◽  
Female Patients

scholarly journals Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer

2010 ◽  
Vol 5 (12) ◽  
pp. 1949-1952 ◽  
Author(s):  
Yoon Hee Choi ◽  
Jin Kyung Lee ◽  
Hye Jin Kang ◽  
Tae Sup Lee ◽  
Hye-Ryoun Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Age At Diagnosis ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Female Patients

Clinical significance of the EML4-ALK fusion gene and association with EGFR and KRASgene mutation in 208 Chinese patients with non-small cell lung cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e17514-e17514 ◽  
Author(s):  
JUN Chen ◽  
Hongyu Liu ◽  
Tong Yang ◽  
Sen Wei ◽  
Qinghua Zhou
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fusion Gene ◽  
Nsclc Patient ◽  
Small Cell ◽  
Chinese Patients ◽  
Small Cell Lung ◽  
Kras Mutations ◽  
Female Patients

e17514 Background: EML4-ALK fusion gene is a potentially relevant oncogenic event in lung cancer, which represents a new subgroup of non-small cell lung cancer (NSCLC) patients who respond positively to ALK inhibitors. The characteristics of EML4-ALK fusion gene in Chinese Patients with NSCLC are poorly understood. In this study, we aimed to analyze the prevalence of EML4-ALK fusion gene and their correlation to epidermal growth factor receptor (EGFR) status, KRAS mutation, and clinico-pathological data in Chinese patients with NSCLC. Methods: Genes were detected by nested RT-PCR and confirmed by sequencing. Results: 208 cases of NSCLC were evaluated. There were 24.5% (51/208 cases of mutations in EGFR at exons 18-21, and EGFR mutations occur predominantly (92%) in exons 19 and 21. In concordance with previous reports, these mutations are identified at high frequencies in females (47.5%, 29/61 vs 15.0%, 22/147 in males; P = 0.000); never-smokers (42.3%, 33/78 vs 13.9%, 18/130 in smokers; P = 0.000), and adenocarcinoma patients (44.2%, 42/95 vs 8.0%, 9/113 in non-adenocarcinoma patients; P = 0.000). There were only 6 cases (6/208, 2.88%) of KRAS mutations in our study group. We identified 7 patients who harbored the EML4-ALK fusion gene (3.37%, 7/208) which all confirmed by DNA sequencing. Of these 7 patients, 2 cases displayed the EML4-ALK variant 1 (28.6%), 1 case exhibited variant 2 (14.3%) and 4 cases carried variant 3 (57.1%). All of the positive cases corresponded to female patients (11.5%, 7/61). Six of the positive cases were non-smokers (7.69%, 6/78). The incidence of EML4-ALK translocation in female non-smoking adenocarcinoma patients is as high as 15.2% (5/33). No EGFR/KRAS mutations were detected among EML4-ALK positive patients. The meta-analysis demonstrated that EML4-ALK translocation was 4.71% (125/2652) in unselected patients with NSCLC, and was also predominant in female patients with adenocarcinoma. Conclusions: EML4-ALK translocations are infrequent in the entire NSCLC patient population, but are frequent in the NSCLC patient subgroup of female, nonsmokers, and adenocarcinoma patients.

P63.15 Clinical Analysis of 89 Female Patients With Small Cell Lung Cancer

2021 ◽  
Vol 16 (10) ◽  
pp. S1188-S1189
Author(s):  
F. Teng ◽  
P. Xing ◽  
K. Yang ◽  
X. Hao ◽  
Y. Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Female Patients

Relationship between loss-of-function mutation of the stromal antigen 2 gene and treatment in non-small cell lung cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20509-e20509
Author(s):  
Minglei Zhuo ◽  
Xin Liu ◽  
Rongrong Chen ◽  
Xiong Xu ◽  
Bin Ni
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Systemic Treatment ◽  
Genetic Alterations ◽  
Small Cell ◽  
Age At Diagnosis ◽  
Loss Of Function ◽  
Small Cell Lung ◽  
The Impact

e20509 Background: The protein encoded by Stromal Antigen 2 ( STAG2) gene is a subunit of the cohesin complex, which regulates the separation of sister chromatids during cell division. Loss-of-function (LOF) mutations of STAG2 gene are commonly detected in different tumors including non-small-cell lung cancer. However, there is no relevant research on the impact of STAG2 alterations on lung cancer treatment. Here we explored the correlation between the LOF of STAG2 and clinical features, concomitant genetic alterations and treatment in NSCLC pts. Methods: A total of 2882 NSCLC pts were enrolled. All the tissue samples were detected by DNA based next generation sequencing (NGS) with a 1021 gene panel. Clinical information was obtained synchronously from physicians and surgeons. According to whether LOF of STAG2 is detected, pts were divided into LOF subgroup and wild type (WT) group. Results: All pts enrolled are Chinese, and median age at diagnosis of them is 63±11.21. Compared to the WT subgroup, a higher average TMB was observed in the LOF group (12.64muts/Mb vs. 6.66mut/Mb, P＜0.05). Between the LOF group and the WT group, there were no significantly difference in all clinical baseline characteristics including age at diagnosis, gender, tumor stage and pathological type. At the time of sample collection, there was no significant difference between the two groups of pts whether they had received systemic treatment (chemotherapy, targeted therapy or immunotherapy) and systemic treatment, and the number of systemic treatment lines received. Neither significant differences in driver gene alteration and other accompanying mutations were observed in the two groups. Conclusions: In NSCLC pts, LOF of STAG2 is not a change after drug resistance, but it may lead to an increase in TMB, which indicates that these pts may have more benefits from immunotherapy. But the influence on prognosis of NSCLC pts needs further research to clarify.

Racial and ethnic disparities in presentation, treatment, and outcomes for minority populations with diagnosis of lung cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e17540-e17540
Author(s):  
Luis E. Raez ◽  
Candice Sareli ◽  
Mark I. Block ◽  
Francisco Tarrazzi ◽  
Evelio Velis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Late Stage ◽  
Cox Regression ◽  
Small Cell ◽  
Age At Diagnosis ◽  
Small Cell Lung ◽  
Tumor Stages ◽  
Significant Difference

e17540 Background: There are differences in the presentation, treatment and outcome of lung cancer patients (pts), based on ethnicity, however there are not enough publications regarding these issues. Methods: Registry data on 2,255 pts with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) treated during last 10 years (2002-2011) at Memorial Health Care System was obtained. The main objective of the study was to evaluate differences in lung cancer survival according to ethnicity. Chi-square was used to compare distribution of tumor stage. Survival curves were compared using log-rank test for each of the tumor stages. Adjusted hazard ratios (AHR) and 95% confidence intervals (95% CI) were reported based on the results of a multivariate Cox regression model for overall survival (OS) with adjustment for gender, age at diagnosis, race, stage and health insurance. Results: A total of 1940 pts (86%) had the diagnosis of NSCLC, the rest were SCLC. There were 1170 (52%) females. Non-Hispanic whites (NHW) were 1,791 pts (79%), Hispanics (H) 266 (12%) and African-American (AA) 149 (7%). Fifty eight percent of patients had stage III/IV at diagnosis. 2054 of the pts were insured (91%). There was a significant difference in age at diagnosis among H (66.5 y), AA (64.4y) and WNH (69.5y). The probability of being diagnosed at a late stage (IIIB/IV) was two times higher among AA compared to NHW (OR= 1.77, P<0.05) or H (OR = 1.67, p<0.05). There was no survival difference between NSCLC and SCLC (19m vs. 16m). Females with NSCLC lived significantly longer than males (Adjusted Hazard ratio (AHR= 1.14 p<0.01). The same was true for SCLC (AHR = 1.43 p < 0.01). Significant predictors for worse survival for patients with NSCLC were: older age at diagnosis (AHR = 1.01, p<0.001), male gender (AHR=1.12, p<0.05) and late stage at diagnosis (AHR=2.27, p<0.001). Insurance and ethnicity were not significant predictors of of survival. Conclusions: There are significant disparities in presentation and outcomes among minority patients with lung cancer. We will further evaluate if other social or genetic factors can explain these disparities.

Female patients with small cell lung cancer live longer than male patients

1988 ◽  
Vol 85 (2) ◽  
pp. 194-196 ◽  
Author(s):  
Bruce E. Johnson ◽  
Seth M. Steinberg ◽  
Ruby Phelps ◽  
Margaret Edison ◽  
Stephen R. Veach ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Female Patients ◽  
Male Patients

scholarly journals Clinical features and outcome of small cell lung cancer in female patients: a large-cohort retrospective study

2020 ◽  
Author(s):  
Jia Hou ◽  
Yu Wang ◽  
Wenyuan Li ◽  
Xiao Wang ◽  
Jincan Hao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Clinical Characteristics ◽  
Distant Metastases ◽  
Small Cell ◽  
Seer Database ◽  
Small Cell Lung ◽  
Female Patients

Abstract Background: Currently, female small cell lung cancer (SCLC) incidence has been increasing. However, there have been few large database-based studies on female patients with SCLC. In this study, we used Surveillance, Epidemiology, and End Results (SEER) database to describe the clinical characteristics and prognosis of female SCLC patients.Methods: SCLC patients from the SEER database between 1973 and 2015 were included. Gender, age, race, stage, tumor size, and metastasis status were included in our study. Clinical characteristics were analyzed among females and males with SCLC. Survival analyses were conducted with log-rank tests and Cox proportional hazard models.Results: A total of 18234 patients were extracted from SEER database. 50.2% of the whole SCLC patients were females. Compared with males, females were less likely to be Asians, carry bigger size of tumor, have later TNM stage, and have distant metastases (P < 0.05). Gender proved to be an independent prognostic factor for SCLC patients (CSS:HR:1.105;95% CI: 1.068 1.143; P < 0.001; OS: HR, 1.120;95% CI: 1.084 1.158; P < 0.001). Female patients presented more favorable survival than male patients (Median OS/CSS:11 vs. 9 months, P < 0.001). Our results confirmed that age≥65, white race, later stage, tumor size ≥ 50mm and distant metastases were all associated with poor prognosis in female patients.Conclusions: Female gender is associated with more favorable outcome of SCLC. For females, patients who are senile, white people, and have poorer pathological features were associated with a shorter OS, which need to be more circumspectly treated in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document